CN-121718496-B - Kiwi skin squamous carcinoma cell line MCSCC14397 and application thereof

Abstract

The invention discloses a macaque skin squamous cell carcinoma cell line MCSCC14397 and application thereof. The macaque skin squamous carcinoma cell line is named as a macaque skin squamous carcinoma cell line MCSCC14397, and the preservation number of the macaque skin squamous carcinoma cell line is CCTCC NO: C2025156. The cell line has similar protein expression with primary tumor tissue, has chromosome abnormal karyotype, in-vitro tumorigenicity and stable proliferation characteristics, and simultaneously shows obvious genome instability (such as high-frequency C > T mutation and structural variation) and inflammatory signal activation. The MYO10 gene expression in the cell line is up-regulated and drives DNA damage response and inflammatory factor expression, and provides unique advantages for the application of the cell line in skin squamous carcinoma mechanism research, drug screening and drug effect evaluation. The cell line can be used as an effective cell model, can be used for establishing a xenograft animal model, and can provide a research foundation for further researching the occurrence, development, transfer mechanism, drug resistance mechanism and innovative drug development and screening of human skin squamous cell carcinoma.

Inventors

• LI LIHONG
• LV LONGBAO
• XIAO LINGLING
• PAN YONGZHANG
• HE YONGHAN

Assignees

• 中国科学院昆明动物研究所

Dates

Publication Date

20260508

Application Date

20260210

Claims (6)

1. 1. The macaque skin squamous cell carcinoma cell line is named as macaque skin squamous cell carcinoma cell line MCSCC14397, and is preserved in China Center for Type Culture Collection (CCTCC) with the preservation number of C2025156 at the month of 2025 and the day of 6.
2. 2. A progeny cell line of the macaque skin squamous cell carcinoma cell line of claim 1.
3. 3. Use of the macaque skin squamous cell carcinoma cell line of claim 1 or the progeny cell line of claim 2 as a cell model of a skin squamous cell carcinoma cell line.
4. 4. Use of the macaque skin squamous cell carcinoma cell line of claim 1 or the progeny cell line of claim 2 as a cell model for skin squamous cell carcinoma occurrence, development and metastasis.
5. 5. Use of the macaque skin squamous cell carcinoma cell line of claim 1 or the progeny cell line of claim 2 for the establishment of an animal model of skin squamous cell carcinoma.
6. 6. Use of the macaque skin squamous cell carcinoma cell line of claim 1 or the progeny cell line of claim 2 for screening for skin squamous cell carcinoma-inhibiting targeted drugs targeting MYO 10.

Description

Kiwi skin squamous carcinoma cell line MCSCC14397 and application thereof Technical Field The invention relates to the technical field of tumor biology, in particular to a macaque skin squamous cell carcinoma cell line MCSCC14397 and application thereof. Background Squamous cell carcinoma of the skin (Cutaneous Squamous Cell Carcinoma, cSCC) is a malignant tumor arising from malignant proliferation of keratinocytes of the epidermis or its accessory structures (such as the pilo-sebaceous unit and the apocrine glands), and has a incidence of 20-50% of skin cancers, the second most common type of skin cancer, and a total mortality of 1.5-3.4%. Squamous cell carcinoma of the skin has a strong metastatic and invasive potential and a poor prognosis, leading to an increasing number of deaths from squamous cell carcinoma of the skin. The disease is clinically manifested as a single hard papule or as a red nodule with a pronounced scaly form, accompanied by a tendency to bleed, with varying degrees of hyperkeratosis, ulcers and other symptoms, which are clearly diagnosed by lesion biopsy and histopathological examination. At present, the pathogenesis of the skin squamous cell carcinoma is not clear, the complete excision recurrence rate under the guidance of histopathology is high, the methods of external application, freezing and the like are related to adverse reactions such as pain, local stimulation, irreversible pigmentation and the like, the compliance is low, and the treatment failure rate is high. Therefore, research on pathogenesis, construction of disease models and development of clinical intervention strategies have become a task with scientific significance and application value. In the field of disease research, the isolation and establishment of cell lines from patient tumor tissue is an important basis for developing transformed medical studies. The cell line provides abundant experimental materials for researching pathogenesis of diseases, constructing a disease model, carrying out drug screening, discovering therapeutic targets and the like. Therefore, establishing a skin squamous cell carcinoma cell line similar to human skin squamous cell carcinoma occurrence, and constructing a proper animal model is an important precondition for researching the skin squamous cell carcinoma disease mechanism and developing a more effective intervention treatment scheme. Squamous carcinoma cell lines, which are derived from surgically resected cancerous tissue or pleural effusions, cover a variety of tissue sources, such as lung (SK-MES-1, NCI-H520), skin, head and neck, etc. Cell morphology predominated by ‌ epithelial-like adherent growth ‌, retaining features typical of squamous carcinoma cells, such as keratinocyte formation and intercellular bridge structure. Long-term passaging of a portion of classical cell lines (e.g., SK-MES-1 established in 1970) may result in a ‌ genetic alteration ‌, impairing its association with the primary tumor. ‌ tumor heterogeneity is manifested insufficiently, single cell sequencing reveals that there is significant heterogeneity of squamous carcinomas, including cancer cells, immune cells, and stromal cell subsets, but traditional cell lines have difficulty mimicking this complex diversity. In vitro culture loses immune cell interaction ‌ in ‌ tumor microenvironment, and in vivo immune escape mechanism cannot be reflected. Cell lines are mostly derived from advanced patients, lack ‌ early stage cancerous stage models ‌, and are difficult to study the mechanism of squamous carcinogenesis (e.g., the dynamic process of bronchial epithelium from hyperplasia to canceration). The existing models have poor predictive effects on the response to immunotherapy, e.g. PD-1 inhibitors have only about 10% response rate in clinical trials. Although the existing squamous cell line provides a basic platform for research, ‌ genetic stability, microenvironment deficiency and heterogeneous reduction deficiency ‌ remain core bottlenecks for limiting clinical transformation. In the future, the reliability of the model needs to be optimized through the cooperation of technical innovation and multidisciplinary, and a molecular typing model which is more similar to clinic is constructed by combining single cell transcriptome and genome analysis. The macaque with spontaneous skin squamous carcinoma has high consistency with human patients in clinical manifestations, pathological features, disease development and the like, can better reproduce typical pathological changes of human patients, has obvious clinical transformation potential, is beneficial to researchers to simulate human disease development, provides a reliable platform for preclinical verification of novel treatment strategies, and is hopeful to accelerate transformation from basic research to clinic. MYO10 is an unstable protein that is upregulated in both human and mouse tumors. MYO10 may promote tumor progression by inducing genomic inst